Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali Sells 1,756 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali sold 1,756 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $46.00, for a total transaction of $80,776.00. Following the completion of the transaction, the chief financial officer now directly owns 61,065 shares in the company, valued at approximately $2,808,990. This trade represents a 2.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Asif Ali also recently made the following trade(s):

• On Wednesday, March 12th, Asif Ali sold 24,903 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $58.73, for a total transaction of $1,462,553.19.

Protagonist Therapeutics Trading Down 0.8 %

PTGX stock opened at $44.49 on Friday. The firm has a market cap of $2.73 billion, a PE ratio of 16.73 and a beta of 2.30. Protagonist Therapeutics, Inc. has a 1 year low of $24.22 and a 1 year high of $60.60. The company has a fifty day simple moving average of $45.58 and a 200 day simple moving average of $42.85.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. As a group, analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PTGX has been the subject of several recent analyst reports. BMO Capital Markets raised their target price on Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. BTIG Research set a $73.00 target price on Protagonist Therapeutics in a research note on Monday, March 3rd. JMP Securities reissued a “market outperform” rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a research report on Friday, February 7th. Truist Financial boosted their price objective on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the company a “buy” rating in a research report on Tuesday, March 11th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $65.44.

Hedge Funds Weigh In On Protagonist Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can boosted its holdings in shares of Protagonist Therapeutics by 4.5% during the 4th quarter. Bank of Montreal Can now owns 6,250 shares of the company’s stock worth $241,000 after buying an additional 270 shares during the period. Maryland State Retirement & Pension System grew its position in shares of Protagonist Therapeutics by 1.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company’s stock valued at $779,000 after purchasing an additional 278 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Protagonist Therapeutics by 10.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock worth $121,000 after purchasing an additional 295 shares during the period. Louisiana State Employees Retirement System lifted its position in shares of Protagonist Therapeutics by 1.1% during the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company’s stock worth $1,112,000 after purchasing an additional 300 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in Protagonist Therapeutics by 153.3% during the 1st quarter. GAMMA Investing LLC now owns 1,203 shares of the company’s stock valued at $58,000 after purchasing an additional 728 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.